RE:RE:Anyone NoticeEoganacht wrote: Nice. Thanks for that. I also noticed this line from the presentation:
"5 Canadian clinical study sites enrolled in Phase II clinical study and treated 14 patients (plus 3 from Phase Ib) out of a target population of ≈ 100 patients"
If they count the 3 full dose patients from phase 1 we are now at 40% CR for the first 15 full dose patients
enriquesuave wrote: "14 patients treated in a pivotal phase II study; 5 sites opened in Canada as of Dec 2020; 25% Complete response with duration of 180 days". So all 4 patients who were CR at 3 months are still CR at 6 months after one single non-optimized treatment. Hello anyone there? For example Vicinium had a 42% CR rate at 3 months which dropped to 28% at 6 months which dropped further to 17% at 12 months, after many many ongoing treatments. No drop in CR from 3 months to 6 months after one single non optimized treatment which was an under treatment of at least 40%, means that we may have some Very nice surprises on our next data read out. All IMO time will tell.
I would also add that the four that were removed (all of whom demonstrated unchanged CIS) would have undergone a 2nd treatment based on the "new" protocol. Though this group would not have been considered a "90 day" CR, they could have very well become a CR (with the possible help of an immune response) or become CR after an optimized 2nd treatment at 6 months. A CR can be achieved at "any" point in time.
So if they count the 3 full dose patients from Ph 1 + the 4 that were removed (considering they had a realistic chance of becoming CR), we are now potentially at "67%" CR for the first 15 patients. The numbers should keep getting better as we optimize all patients moving forward. All imo.